IL166010A0 - Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1 - Google Patents

Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1

Info

Publication number
IL166010A0
IL166010A0 IL16601004A IL16601004A IL166010A0 IL 166010 A0 IL166010 A0 IL 166010A0 IL 16601004 A IL16601004 A IL 16601004A IL 16601004 A IL16601004 A IL 16601004A IL 166010 A0 IL166010 A0 IL 166010A0
Authority
IL
Israel
Prior art keywords
mip
selective inhibitors
piperidine derivatives
receptor ccr1
1alpha
Prior art date
Application number
IL16601004A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL166010A0 publication Critical patent/IL166010A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16601004A 2002-07-18 2004-12-27 Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1 IL166010A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39710802P 2002-07-18 2002-07-18
PCT/IB2003/002876 WO2004009550A1 (en) 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1

Publications (1)

Publication Number Publication Date
IL166010A0 true IL166010A0 (en) 2006-01-15

Family

ID=30770997

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16601004A IL166010A0 (en) 2002-07-18 2004-12-27 Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1

Country Status (24)

Country Link
US (1) US20040063759A1 (xx)
EP (1) EP1534677A1 (xx)
JP (1) JP2005537279A (xx)
KR (1) KR20050021497A (xx)
CN (1) CN1668592A (xx)
AP (1) AP2005003200A0 (xx)
AR (1) AR040583A1 (xx)
AU (1) AU2003242941A1 (xx)
BR (1) BR0312946A (xx)
CA (1) CA2492651A1 (xx)
EC (1) ECSP055547A (xx)
HN (1) HN2003000222A (xx)
IL (1) IL166010A0 (xx)
IS (1) IS7614A (xx)
MA (1) MA27326A1 (xx)
MX (1) MXPA05000380A (xx)
OA (1) OA12885A (xx)
PA (1) PA8575901A1 (xx)
PE (1) PE20040666A1 (xx)
TN (1) TNSN05014A1 (xx)
TW (1) TW200402416A (xx)
UY (1) UY27897A1 (xx)
WO (1) WO2004009550A1 (xx)
ZA (1) ZA200500067B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions
CN1867336B (zh) 2002-06-12 2010-05-12 凯莫森特里克斯股份有限公司 1-芳基-4-取代的哌嗪衍生物及其制药用途
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
EA200500033A1 (ru) * 2002-07-18 2005-06-30 Пфайзер Продактс Инк. Бициклические производные пиперидина в качестве антагонистов хемокинового рецептора ccr1
US8261062B2 (en) 2003-03-27 2012-09-04 Microsoft Corporation Non-cryptographic addressing
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
EP1720545B1 (en) 2004-03-03 2014-10-29 ChemoCentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7929689B2 (en) 2004-06-30 2011-04-19 Microsoft Corporation Call signs
GT200500375A (es) * 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
US7620902B2 (en) 2005-04-20 2009-11-17 Microsoft Corporation Collaboration spaces
US7617281B2 (en) 2005-04-25 2009-11-10 Microsoft Corporation System and method for collaboration with serverless presence
US7660851B2 (en) 2005-07-06 2010-02-09 Microsoft Corporation Meetings near me
JP4938777B2 (ja) 2005-07-26 2012-05-23 グラクソ グループ リミテッド ベンジルピペラジン誘導体およびその医薬使用
US7576218B2 (en) 2005-10-11 2009-08-18 Chemocentryx, Inc. 4-phenylpiperdine-pyrazole CCR1 antagonists
US8069208B2 (en) 2006-04-21 2011-11-29 Microsoft Corporation Peer-to-peer buddy request and response
US8086842B2 (en) 2006-04-21 2011-12-27 Microsoft Corporation Peer-to-peer contact exchange
EP2202223B1 (en) * 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent
US20100168080A1 (en) * 2008-12-17 2010-07-01 Khamrai Uttam Novel compounds useful as cc chemokine receptor ligands
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (xx) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
EP1179341B1 (en) * 1999-05-18 2005-11-09 Teijin Limited Remedies or preventives for diseases in association with chemokines
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
SI1409477T1 (sl) * 2001-07-24 2009-02-28 Richter Gedeon Nyrt Derivati piperidina kot antagonisti nmda-receptorjev

Also Published As

Publication number Publication date
AU2003242941A1 (en) 2004-02-09
TW200402416A (en) 2004-02-16
HN2003000222A (es) 2004-11-23
MA27326A1 (fr) 2005-05-02
WO2004009550A1 (en) 2004-01-29
CA2492651A1 (en) 2004-01-29
BR0312946A (pt) 2005-07-12
OA12885A (en) 2006-09-15
UY27897A1 (es) 2004-02-27
MXPA05000380A (es) 2005-03-31
IS7614A (is) 2004-12-23
EP1534677A1 (en) 2005-06-01
US20040063759A1 (en) 2004-04-01
ZA200500067B (en) 2005-11-02
PA8575901A1 (es) 2004-07-20
CN1668592A (zh) 2005-09-14
JP2005537279A (ja) 2005-12-08
KR20050021497A (ko) 2005-03-07
AR040583A1 (es) 2005-04-13
ECSP055547A (es) 2005-03-10
TNSN05014A1 (fr) 2007-05-14
PE20040666A1 (es) 2004-09-25
AP2005003200A0 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
IL166010A0 (en) Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
HK1094203A1 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
AU2003298514A8 (en) Methods and compositions using cholinesterase inhibitors
IL173398A0 (en) Pyridyl derivatives and their use as therapeutic agents
IL174334A0 (en) Use of chk1 inhibitors to control cell proliferation
EP1601357A4 (en) HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
IL182527A0 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
EP1656378A4 (en) COMPOUNDS AND COMPOSITIONS INHIBITING TYROSINE KINASE RECEPTOR ACTIVITY
IL175179A0 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EP1603567A4 (en) TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF
AU2003302919A1 (en) Pyridine derivatives as jnk inhibitors and their use
IL174497A0 (en) Pyridine derivatives and use thereof as urotensin ii antagonists
IL176772A0 (en) Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors
EP1763346A4 (en) COMPOSITION AND METHODS RELATING TO INHIBITORS OF PYRIMIDINE SYNTHESIS
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
ZA200606070B (en) Substituted quinolines and their use as mycrobacterial inhibitors
AU2003215756A8 (en) Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
EP1703907A4 (en) COMPOSITIONS AND METHODS FOR TREATING RECURRENT CONDITIONS
IL179038A0 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
EP1627048A4 (en) Compositions for Downregulating CCR5 Expression and Method of Use Therefor
AU2003218715A8 (en) Azepane derivatives and their use as atk1 inhibitors
GB0611789D0 (en) Methods and compositions relating to ccr5 antagonist,ifn-&gammed;and il-13 induced inflammation
AU2003231019A8 (en) Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
ZA200607436B (en) Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma